FrancophonIA/ELRC3.0 huggingface dataset:
English: In cattle, Inflacam is used together with appropriate antibiotic therapy, to reduce clinical signs of acute respiratory infection (infection of the lungs and airways).
Estonian: Veistel kasutatakse Inflacami ägeda respiratoorse infektsiooni (kopsude ja hingamisteede nakkuse) kliiniliste sümptomite vähendamiseks koos sobiva antibiootikumraviga.
English: It can be used with oral re-hydration therapy (medicines given by mouth to restore water levels in the body) to reduce diarrhoea in calves of over one week of age and young, non-lactating cattle.
Estonian: Seda tohib kasutada kõhulahtisuse leevendamiseks koos suukaudse rehüdratsioonraviga (organismi vedelikusisaldust taastava raviga) üle nädala vanustel vasikatel ja mullikatel.
English: In horses, Inflacam is used to reduce pain associated with colic (abdominal pain) and to lessen inflammation and relieve pain in acute and chronic musculo-skeletal disorders (disorders affecting the muscles and bones).
Estonian: Hobustel kasutatakse Metacami voolmete (kõhuvalu) ning põletiku ja valu leevendamiseks ägedate ja krooniliste luu- ja lihaskonna vaevuste korral.
English: The precautions are the same as for the reference medicine since Inflacam is a generic medicine.
Estonian: Et Inflacam on geneeriline ravim, siis on meetmed samad, mis võrdlusravimi korral.
English: Why is Inflacam authorised in the EU?
Estonian: Inflacami Euroopa Liidus heakskiitmise põhjused
English: Avelox was initially approved in June 1999.
Estonian: Aveloxle anti müügiluba esimest korda 1999. aasta juunis.
English: Avelox film-coated tablets contain 400 mg moxifloxacin as hydrochloride.
Estonian: Avelox õhukese polümeerikattega tabletid sisaldavad 400 mg moksifloksatsiini hüdrokloriidina.
English: COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) OPINION FOLLOWING AN ARTICLE 6 (12) REFERRAL Avelox and associated names International non-proprietary name (INN): moxifloxacin BACKGROUND INFORMATION *
Estonian: INIMRAVIMITE KOMITEE ARVAMUS PÄRAST ARTIKLI 6 LÕIKE 12 ALUSEL TEHTUD ESILDIST Avelox ja sarnased nimetused Rahvusvaheline mittekaubanduslik nimetus (INN): moksifloksatsiin TAUSTTEAVE*
English: This summary was last updated in 04-2014.
Estonian: Kokkuvõtte viimane uuendus: 04-2014
English: The European Commission granted a marketing authorisation valid throughout the European Union for Hemangiol on 23 April 2014.
Estonian: Euroopa Komisjon andis Hemangioli müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 23. Aprillil 2014.
English: Treatment should be started in appropriate facilities in case serious side effects develop.
Estonian: Ravi tuleb alustada sobivates asutustes juhuks, kui tekivad rasked kõrvalnähud.
English: The full EPAR and risk management plan summary for Hemangiol can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ja riskijuhtimiskava kokkuvõte Hemangioli kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Regarding safety, the CHMP considered that the safety profile is acceptable; the risks identified are those already known for propranolol and can be appropriately managed.
Estonian: Ohutuse osas arvas inimravimite komitee, et ohutusprofiil on vastuvõetav; tuvastatud riskid on sellised, mis on propranolooli kohta juba teada ja mida saab piisavalt hästi ohjata.
English: Hemangiol propranolol
Estonian: Hemangiol propranolool
English: What measures are being taken to ensure the safe and effective use of Hemangiol?
Estonian: Mis meetmed võetakse, et tagada Hemangioli ohutu ja efektiivne kasutamine?
English: A risk management plan has been developed to ensure that Hemangiol is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Hemangioli võimalikult ohutu kasutamine.
English: It will also provide instructions on how to give the medicine correctly, in order to avoid the risk of low blood sugar levels.
Estonian: Ettevõte annab ka juhised, kuidas ravimit õigesti anda, et vältida vereglükoosi sisalduse vähenemise riski.
English: Treatment with Hemangiol is started in babies aged five weeks to five months.
Estonian: Hemangioli ravi alustatakse beebidel vanuses viis nädalat kuni viis kuud.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Hemangiol's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Inimravimite komitee otsustas, et Hemangioli kasulikkus on suurem kui sellega kaasnevad riskid ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: Other information about Hemangiol
Estonian: Muu teave Hemangioli kohta
English: Treatment with Hemangiol should last for six months and the child should be monitored once a month, in particular for dose adjustments.
Estonian: Hemangioli ravi peab kestma kuus kuud ja last tuleb jälgida kord kuus, eriti annuse kohandamiseks.
English: The Company will provide caregivers who will give Hemangiol to children with an educational pack to inform them of the need to monitor children for certain side effects and how to manage them.
Estonian: Ettevõte annab hooldajatele, kes lastele Hemangioli annavad, teabepakme, et teatada neile vajadusest jälgida lapsi teatud kõrvalnähtude tuvastamise ja nende ohjeldamise osas.
English: Hemangiol is a medicine that contains the active substance propranolol.
Estonian: Hemangiol on ravim, mis sisaldab toimeainena propranolooli.
English: Hemangiol was investigated in one main study involving 460 children aged from five weeks to five months at the start of treatment and who had proliferative infantile haemangioma that required systemic therapy.
Estonian: Hemangioli uuriti ühes põhiuuringus, mis hõlmas 460 last, kes olid ravi alustamisel vanuses 5 nädalat kuni 5 kuud ja kellel oli süstemaatilist ravi nõudev prolifereeruv infantiilne hemangioom.
English: Hemangiol must not be used in: premature babies who have not reached the corrected age of 5 weeks (the corrected age is the age a premature baby would be if he/she had been born on the due date); breastfed children if the mother is being treated with medicines that must not be used with propranolol; children with asthma or with a history of bronchospasm; children with certain diseases of the heart and blood vessels, such as low blood pressure; and children who tend to have low blood sugar levels.
Estonian: Hemangioli ei tohi kasutada enneaegsetel imikutel, kes pole jõudnud korrigeeritud vanuseni 5 nädalat (korrigeeritud vanus on see, kui vana enneaegne beebi oleks siis, kui ta oleks sündinud tähtaegselt); rinnapiimatoidul lastel, kui ema ravitakse ravimitega, mida propranolooliga ei tohi kasutada; astma või bronhospasmi haiguslooga lastel; teatud südame- ja veresoonte haigustega (nt madal vererõhk) lastel; ja lastel, kellel vereglükoosi väikest sisaldust.
English: What is Hemangiol and what is it used for?
Estonian: Mis on Hemangiol ja milleks seda kasutatakse?
English: Hemangiol is used in infants with serious complications, such as painful ulcers, scarring and breathing difficulties, who require systemic therapy (treatment which can have an effect on the whole body).
Estonian: Hemangioli kasutatakse raskete tüsistustega (nt valulikud haavandid, armid ja hingamisraskused) väikelaste puhul, kes vajavad süsteemset ravi (ravi, mis võib mõjutada kogu organismi).
English: The dose is given to the baby during or immediately after a feed using the oral syringe provided.
Estonian: Ravimiannus antakse beebile toitmise käigus või kohe pärast seda, kasutades kaasasolevat suusüstalt.
English: Why is Hemangiol approved?
Estonian: Miks Hemangiol heaks kiideti?
English: In around 60% (61 out of 101) of children treated with the most effective dose of Hemangiol (3 mg/kg/day for 6 months), haemangiomas disappeared completely or almost completely compared with around 4% (2 out of 55) in children who received placebo.
Estonian: 60% lastest (61 last 101-st), keda raviti Hemangioli kõige efektiivsema annusega (3 mg/kg/ööpäev, 6 kuud), kadusid hemangioomid täielikult või peaaegu täielikult võrreldes umbes 4%-ga lastest (2 last 55st), kellele manustati platseebot.
English: The Committee concluded that Hemangiol was an effective treatment for haemangioma.
Estonian: Komitee jõudis järeldusele, et Hemangiol oli hemangioomi ravimisel efektiivne.
English: The active substance in Hemangiol, propranolol, belongs to a group of medicines called beta-blockers, which have been widely used to treat several conditions in adults, including diseases of the heart and high blood pressure.
Estonian: Hemangioli toimeaine propranolool kuulub ravimite rühma nimega beetablokaatorid, mida on laialdaselt kasutatud mitmete haiguste ravimiseks täiskasvanutel, sealhulgas südamehaigused ja kõrge vererõhk.
English: Serious side effects observed with Hemangiol include bronchospasm (temporary narrowing of the airways) and low blood pressure.
Estonian: Hemangioliga täheldatud rasked kõrvalnähud hõlmavad bronhospasmi (hingamisteede ajutine ahenemine) ja madalat vererõhku.
English: This is a summary of the European public assessment report (EPAR) for Hemangiol.
Estonian: See on ravimi Hemangiol Euroopa avaliku hindamisaruande kokkuvõte.
English: Although it is not exactly known how Hemangiol works in proliferative infantile haemangioma, it is thought to do so by several mechanisms including narrowing the blood vessels and so decreasing blood supply to the haemangioma, blocking the formation of new blood vessels in the growth, triggering cell death of the abnormal blood vessel cells and blocking the effect of certain proteins (called VEGF and bFGF), which are important for the growth of blood vessels.
Estonian: Kuigi Hemangioli toime prolifereeruva infantiilse hemangioomi korral ei ole täpselt teada, arvatakse, et see toimib eri mehhanismide kaudu, sealhulgas veresoonte ahendamine ja seeläbi hemangioomi verevarustuse vähendamine, kasvajas uute veresoonte tekkimise blokeerimine, ebanormaalsete veresoonte rakkude hävitamine ja veresoonte kasvamiseks vajalike teatud valkude (VEGF ja bFGF) toime blokeerimine.
English: The recommended starting dose of Hemangiol is 0.5 mg per kilogram bodyweight (0.5 mg/kg), twice a day (at least 9 hours apart).
Estonian: Hemangioli soovitatav algannus on 0,5 mg kehamassi kilogrammi kohta (0,5 mg/kg), kaks korda ööpäevas (vähemalt 9-tunniste vahedega).
English: The most common side effects with Hemangiol (which may affect more than 1 in 10 children) are sleep disorders, respiratory tract infections such as bronchitis (inflammation of the airways in the lungs), diarrhoea and vomiting.
Estonian: Hemangioli kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 lapsel 10st) on unehäired, hingamisteede infektsioonid, nagu bronhiit (kopsubronhide põletik), kõhulahtisus ja oksendamine.
English: What are the risks associated with Hemangiol?
Estonian: Mis riskid Hemangioliga kaasnevad?
English: The study compared different doses of propranolol with placebo (a dummy treatment) and the main measure of effectiveness was based on whether the haemangiomas disappeared completely or almost completely after 6 months of treatment.
Estonian: Uuringus võrreldi propranolooli eri annuseid platseeboga (näiv ravim) ja efektiivsuse põhinäitaja oli see, kas hemangioomid kadusid pärast 6 kuu pikkust ravi täielikult või peaaegu täielikult.
English: The dose is progressively increased to a maintenance dose of 1.5 mg/kg twice a day.
Estonian: Annust tuleb pidavalt suurendada säilitusannuseni 1,5 mg/kg kaks korda ööpäevas.
English: It is not intended to provide practical advice on how to use Hemangiol.
Estonian: Hindamisaruandes ei anta Hemangioli kasutamise praktilisi nõuandeid.
English: Treatment should be started by a doctor who has experience in the diagnosis, treatment and management of infantile haemangioma.
Estonian: Ravi tohib alustada üksnes infantiilse hemangioomi diagnoosimises, ravis ja ravikorralduses kogenud arst.
English: For practical information about using Hemangiol, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Hemangioli kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: For the full list of all side effects reported with Hemangiol, see the package leaflet.
Estonian: Hemangioli kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Hemangiol, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Hemangioli omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: For more information about treatment with Hemangiol, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Hemangioliga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: How does Hemangiol work?
Estonian: Kuidas Hemangiol toimib?
English: Hemangiol at a dose of 3 mg/kg per day (given as two separate doses of 1.5 mg/kg) given for 6 months was shown to be more effective than placebo.
Estonian: Uuringus ilmnes, et Hemangiol annuses 3 mg/kg ööpäevas (antuna kahe eri annusena, kumbki 1,5 mg/kg) 6 kuu jooksul oli efektiivsem kui platseebo.
English: How is Hemangiol used?
Estonian: Kuidas Hemangioli kasutatakse?
English: What benefits of Hemangiol have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Hemangioli kasulikkus?
English: It is used to treat children with proliferating infantile haemangioma, which are benign tumours (abnormal non-cancerous growths) of blood vessels.
Estonian: Seda kasutatakse selliste laste ravimiseks, kellel on prolifereeruv infantiilne hemangioom ehk veresoonte healoomuline kasvaja.
English: Hemangiol is available as a solution to be taken by mouth.
Estonian: Hemangioli turustatakse suukaudse lahusena.
English: Hemangiol can only be obtained with a prescription.
Estonian: Hemangiol on retseptiravim.
English: Adopted at the 9-12 April 2018 PRAC
Estonian: Vastu võetud ravimiohutuse riskihindamise komitee 9.-12. aprilli 2018 koosolekul
English: Swelling of the face, lips, tongue or throat
Estonian: Näo, huulte, keele või kõri turse
English: Not known: frequency cannot be estimated from available data
Estonian: Teadmata: esinemissagedust ei saa hinnata olemasolevate andmete alusel
English: Phenprocoumon is contraindicated during pregnancy (see section 4.3).
Estonian: Fenprokumoon on raseduse ajal vastunäidustatud (vt lõik 4.3).
English: Women of childbearing potential planning a pregnancy should be switched to a safer alternative treatment prior to pregnancy.
Estonian: Rasestumisvõimelised naised, kes planeerivad rasedust, peavad enne rasestumist üle minema muule ohutumale ravile.
English: There is epidemiological evidence suggesting that the risk of birth defects and foetal death increases with the increasing duration of exposure to phenprocoumon during the first trimester of pregnancy, with a steep increase of the rate of major birth defects when phenprocoumon treatment is continued beyond the 5th gestational week.
Estonian: Epidemioloogiliste andmete kohaselt suureneb kaasasündinud väärarendite ja loote surma risk korrelatsioonis fenprokumooniga kokkupuute kestusega esimesel rasedustrimestril, kusjuures raskete kaasasündinud väärarendite risk suureneb järsult, kui fenprokumoonravi jätkatakse pärast 5. rasedusnädalat.
English: Lapatinib - Pulmonary hypertension (EPITT no 19089)
Estonian: Lapatiniib - pulmonaalne hüpertensioon (EPITT nr 19089)
English: Frequency not known: pulmonary arterial hypertension
Estonian: Esinemissagedus teadmata: pulmonaalhüpertensioon
English: If you wish to get pregnant or if you already became pregnant while taking this medicine, talk to your doctor immediately as you should be switched to a safer alternative treatment (e.g. heparin) if you are planning a pregnancy or immediately after recognition of pregnancy.
Estonian: Kui võtate seda ravimit ja soovite rasestuda või olete juba rase, pidage otsekohe nõu oma arstiga, sest raseduse planeerimisel või otsekohe pärast raseduse tuvastamist peate hakkama kasutama muud, ohutumat ravi (nt hepariini).
English: Therefore, if you are breastfeeding, your child should receive vitamin K1.
Estonian: Seetõttu tuleb imetatavale lapsele anda K1-vitamiini.
English: Package leaflet 4.
Estonian: Tabel 2.
English: As a precaution, however, prophylaxis involving the administration of vitamin K1 to the infant concerned is recommended.
Estonian: Ettevaatusabinõuna on aga soovitatav manustada rinnapiimaga toidetavale imikule profülaktiliselt K1-vitamiini.
English: Phenprocoumon - Risk of birth defects and foetal loss following first trimester exposure as a function of the time of withdrawal (EPITT no 18902)
Estonian: Fenprokumoon - ravi lõpetamise ajast sõltuv kaasasündinud väärarendite ja loote surma risk pärast kokkupuudet esimesel trimestril (EPITT nr 18902)
English: In humans phenprocoumon crosses the placental barrier.
Estonian: Inimesel läbib fenprokumoon platsentabarjääri.
English: If the patient becomes pregnant while taking <…>, the patient should immediately be switched to a safer alternative treatment (e.g. heparin) and close follow-up including level II ultrasound should be recommended.
Estonian: Kui patsient <ravimi nimetus omastavas käändes> kasutamise ajal rasestub, peab ta otsekohe üle minema muule ohutumale ravile (nt hepariin) ning soovitatav on järelkontroll, sh loote anatoomia ultraheliuuring.
English: In cases of exposure to phenprocoumon during second and third trimester of pregnancy, the foetus is at an increased risk of intrauterine or parturitional (cerebral) hemorrhage due to foetal anticoagulation.
Estonian: Kui kokkupuude fenprokumooniga toimub teisel või kolmandal rasedustrimestril, on lootel suurem risk antikoagulatsioonist põhjustatud (aju-)verejooksu tekkeks üsasiseselt või sünnituse ajal.
English: Amitriptyline - Dry eye (EPITT no 19173)
Estonian: Amitriptüliin - silmakuivus (EPITT nr 19173)
English: This means taking <...> during pregnancy can lead to malformations and even death of your unborn child.
Estonian: See tähendab, et <ravimi nimetus omastavas käändes> võtmine raseduse ajal võib põhjustada loote väärarendeid ja isegi loote surma.
English: Common: pneumonia (including bacterial, viral, and fungal), upper respiratory tract infection/inflammation, herpes virus infection (including cytomegalovirus-CMV), enterocolitis infection, sepsis (including uncommon cases with fatal outcomes)
Estonian: Sage: kopsupõletik (nii bakteriaalne, viiruslik kui seennakkus), ülemiste hingamisteede infektsioon/põletik, herpesviiruse infektsioon (sh tsütomegaloviiruse (CMV) infektsioon), enterokoliit, sepsis (sh aeg-ajalt esinenud letaalse lõppega juhud)
English: Possible side effects Frequency ‘not known': Dry eyes
Estonian: Võimalikud kõrvaltoimed Esinemissagedus „teadmata“: silmakuivus
English: Based on human experience phenprocoumon may cause birth defects and foetal death when administered during pregnancy.
Estonian: Olemasoleva kogemuse põhjal võib fenprokumooni manustamine raseduse ajal inimesele põhjustada kaasasündinud väärarendeid ja loote surma.
English: In nursing mothers, the active ingredient passes into the breast milk, though in such small amounts that no adverse reactions are likely to occur in the infant.
Estonian: Imetamisel eritub toimeaine rinnapiima, kuid nii väikeses koguses, et tõenäoliselt ei tekita see imikule kõrvaltoimeid.
English: Common side effects (may affect up to 1 in 10 people) Infections: pneumonia, herpes virus infection (including cytomegalovirus-CMV), upper respiratory tract infection, serious infection of the blood or tissues (including uncommon cases with fatal outcomes)
Estonian: Infektsioonid: kopsupõletik, herpesviiruse infektsioon (sh tsütomegaloviiruse (CMV) infektsioon), ülemiste hingamisteede infektsioon, vere või kudede raske infektsioon (kaasa arvatud aeg-ajalt letaalse lõppega esinenud juhud)
English: Undesirable effects Tabulated list of adverse reactions Skin and subcutaneous tissue disorders Frequency ‘not known': Angioedema, urticaria
Estonian: Naha ja nahaaluskoe kahjustused Esinemissagedus „teadmata“: angioödeem, urtikaaria
English: If you are breastfeeding, <…> passes into the breast milk, though in such small amounts that no adverse reactions are likely to occur to your child.
Estonian: Imetamisel eritub <ravimi nimetus> rinnapiima, kuid nii väikeses koguses, et see ei tekita lapsele tõenäoliselt kõrvaltoimeid.
English: Women of childbearing age who are taking <…> have to use effective contraceptive measures during treatment and should continue for 3 months after the last dose.
Estonian: Rasestumisvõimelised naised / rasestumisvastased vahendid Fertiilses eas naised, kes võtavad <ravimi nimetus osastavas käändes>, peavad ravi ajal ja 3 kuu jooksul pärast viimast annust kasutama efektiivseid rasestumisvastaseid vahendeid.
English: Dasatinib - Cytomegalovirus (CMV) reactivation (EPITT no
Estonian: Dasatiniib - tsütomegaloviirusinfektsiooni (CMV) reaktiveerumine (EPITT nr 19111)
English: Frequency not known: pulmonary arterial hypertension (increased blood pressure in the arteries (blood vessels) of the lungs)
Estonian: Esinemissagedus teadmata: kopsuvereringe hüpertensioon (vererõhu kõrgenemine kopsuarterites)
English: Undesirable effects Under SOC ‘Eye disorders' Frequency ‘not known': Dry eye
Estonian: Organsüsteemi klass „Silma kahjustused“ Esinemissagedus „teadmata“: silmakuivus
English: No information on effects of <…> on fertility is available.
Estonian: Andmed <ravimi nimetus omastavas käändes> toime kohta fertiilsusele puuduvad.
English: You must prevent becoming pregnant by taking effective contraceptive measures during therapy with <…> and in the period of 3 months after completion of the treatment with <…> due to the increased risk of foetal malformations.
Estonian: Loote väärarendite riski tõttu tuleb <ravimi nimetus>-ravi ajal ja 3 kuud pärast <ravimi nimetus>-ravi lõppu kasutada tõhusaid rasestumisvastaseid vahendeid.
English: Vortioxetine - Angioedema and urticaria (EPITT no
Estonian: Vortioksetiin - angioödeem ja urtikaaria (EPITT nr 19099)
English: There is also a risk of bleeding in the foetus (foetal hemorrhage).
Estonian: Samuti võib see lootel põhjustada verejooksu.
English: You must not use <…> when you are pregnant, as it passes from mother to child.
Estonian: Kui olete rase, ärge <ravimi nimetus osastavas käändes> kasutage, sest ravim võib kahjustada loodet.
English: Summary of product characteristics
Estonian: Kõrvaltoimete tabel
English: Hives
Estonian: Kõrvaltoimed
English: This is a normal observation.
Estonian: See on normaalne tähelepanek.
English: These reactions resolve over an average of 4 days.
Estonian: Need reaktsioonid taanduvad keskmiselt 4 päeva jooksul.
English: Efficacy study (NIH sponsored)
Estonian: Efektiivsusuuring (NIH sponsoreeritud)
English: The cough may last for one to two months or longer.
Estonian: Köha võib kesta üks kuni kaks kuud või kauem.
English: Ask your pharmacist how to throw away medicines your child no longer uses.
Estonian: Küsige oma apteekrilt, kuidas visata ära ravimeid, mida te enam ei kasuta.
English: This includes the muscles needed for breathing and walking.
Estonian: Siia kuuluvad ka need lihased, mida vajatakse hingamiseks ja kõndimiseks.
English: This will protect your child against these diseases.
Estonian: See kaitseb teie last nende haiguste eest.
English: Each individual pack cannot be sold separately
Estonian: Iga üksikut pakendit eraldi ei müüda
English: The clinical relevance of these observations remains unknown.
Estonian: Nende tähelepanekute kliiniline tähtsus ei ole teada.
English: How much is given
Estonian: Kui palju seda manustatakse
English: Stability data indicate that the vaccine components are stable at temperatures up to 25°C for 72 hours.
Estonian: Stabiilsusandmed näitavad, et vaktsiini komponendid on temperatuuril kuni 25 °C stabiilsed 72 tundi.